What is the role of moxetumomab pasudotox in the treatment of hairy cell leukemia?

Updated: Jan 16, 2019
  • Author: Sandy D Kotiah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Moxetumomab pasudotox

Moxetumomab pasudotox is an anti-CD22 recombinant immunotoxin indicated for adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least 2 prior systemic therapies, including a purine nucleoside analog. [16]

Dose: 0.04 mg/kg IV on days 1, 3, and 5 of each 28-day cycle; infuse over 30 minutes; continue for maximum of 6 cycles or until disease progression or unacceptable toxicity occurs.

Drugs that are being evaluated in clinical trials include ibrutinib (first class oral inhibitor of Bruton kinase) and BRAF V600E inhibitors as the majority of classic HCL harbors the BRAF mutation. [17]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!